Search Results - "Strunz-McKendry, T." :: K.UTB vyhledávací portál

sFlt‐1/PlGF ratio test for pre‐eclampsia: an economic assessment for the UK

by Vatish, M., Strunz‐McKendry, T., Hund, M., Allegranza, D., Wolf, C., Smare, C.
Published in Ultrasound in obstetrics & gynecology (01.12.2016)

Get full text

Journal Article

Loading…

Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC: A Payer Perspective in the United Kingdom

by Towse, A, Gavaghan, M, Strunz-McKendry, T, Garfield, S, Poulios, N
Published in Value in health (01.11.2013)

Get full text

Journal Article

Loading…

2001P Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study

by Joly Lobbedez, F., Roupret, M., Culine, S., Tricotel, A., Casarotto, E., Minacori, R., Strunz-McKendry, T., Karzazi, K., Leyland, K., Vuillet, M., Thomas, M-C.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

Loading…

PCR271 Health-Related Quality of Life (HRQOL) by Line of Treatment, Treatment History, and Disease Status in Patients With Metastatic Urothelial Carcinoma (MUC) in EU-4 and the United Kingdom: Results From a Disease Specific Programme

by Hasaligil, A, Munro, V, Strunz-McKendry, T, Wang-Silvanto, J, Milloy, N, Berry, M, Montgomery, R, De Santis, M
Published in Value in health (01.12.2022)

Get full text

Journal Article

Loading…

$PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma$

PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma

by Davé, K., Strunz-McKendry, T., Felizzi, F., Launonen, A., Krivasi, T.
Published in Value in health (01.12.2020)

Get full text

Journal Article

Loading…

PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES

by Huntington, S.F., Strunz-McKendry, T., Masaquel, A.S., Shapouri, S., Sail, K., Durno, N., Mato, A.
Published in Value in health (01.05.2019)

Get full text

Journal Article

Loading…

PCN103 - Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC: A Payer Perspective in the United Kingdom

by Towse, A., Gavaghan, M., Strunz-McKendry, T., Garfield, S., Poulios, N.
Published in Value in health (01.11.2013)

Get full text

Journal Article

sFlt‐1/PlGF ratio test for pre‐eclampsia: an economic assessment for the UK

Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC: A Payer Perspective in the United Kingdom

2001P Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study

PCR271 Health-Related Quality of Life (HRQOL) by Line of Treatment, Treatment History, and Disease Status in Patients With Metastatic Urothelial Carcinoma (MUC) in EU-4 and the United Kingdom: Results From a Disease Specific Programme

PCN245 Opposing Duration of Treatment Effect Assumptions USED in the Health Technology Assessment of a Treatment for Rituximab-Refractory Follicular Lymphoma

PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES

PCN103 - Cost-Effectiveness of Cobas® EGFR Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic NSCLC: A Payer Perspective in the United Kingdom

Refine Results

Format

Subject Area

Topic

Language

Year of Publication

Database